These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 23759176)

  • 1. [Hallucinogen persisting perception disorder after ecstasy use].
    Hanck L; Schellekens AF
    Ned Tijdschr Geneeskd; 2013; 157(24):A5649. PubMed ID: 23759176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Hallucinogen Persisting Perception Disorder (HPPD) and Flashback Phenomena – Differential Diagnosis and Explanation Models].
    Hermle L; Ruchsow M; Täschner KL
    Fortschr Neurol Psychiatr; 2015 Sep; 83(9):506-15. PubMed ID: 26421858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD.
    Halpern JH; Lerner AG; Passie T
    Curr Top Behav Neurosci; 2018; 36():333-360. PubMed ID: 27822679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Migraine prevalence in visual snow with prior illicit drug use (hallucinogen persisting perception disorder) versus without.
    van Dongen RM; Alderliefste GJ; Onderwater GLJ; Ferrari MD; Terwindt GM
    Eur J Neurol; 2021 Aug; 28(8):2631-2638. PubMed ID: 33979006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram.
    Liechti ME; Baumann C; Gamma A; Vollenweider FX
    Neuropsychopharmacology; 2000 May; 22(5):513-21. PubMed ID: 10731626
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse symptomatology and suicide associated with the use of methylenedioxymethamphetamine (MDMA; "Ecstasy").
    Cohen RS
    Biol Psychiatry; 1996 May; 39(9):819-20. PubMed ID: 8731525
    [No Abstract]   [Full Text] [Related]  

  • 7. LSD-induced Hallucinogen Persisting Perception Disorder with depressive features treated with reboxetine: case report.
    Lerner AG; Shufman E; Kodesh A; Kretzmer G; Sigal M
    Isr J Psychiatry Relat Sci; 2002; 39(2):100-3. PubMed ID: 12227224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interaction of serotonin reuptake inhibitor and 3,4-methylenedioxymethamphetamine?
    Lauerma H; Wuorela M; Halme M
    Biol Psychiatry; 1998 Jun; 43(12):929. PubMed ID: 9627751
    [No Abstract]   [Full Text] [Related]  

  • 9. Hallucinogen persisting perceptual disorder: a scoping review covering frequency, risk factors, prevention, and treatment.
    Doyle MA; Ling S; Lui LMW; Fragnelli P; Teopiz KM; Ho R; Di Vincenzo JD; Rosenblat JD; Gillissie ES; Nogo D; Ceban F; Jawad MY; McIntyre RS
    Expert Opin Drug Saf; 2022 Jun; 21(6):733-743. PubMed ID: 35426769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics of individuals with schizophrenia and hallucinogen persisting perception disorder: a preliminary investigation.
    Lev-Ran S; Feingold D; Frenkel A; Lerner AG
    J Dual Diagn; 2014; 10(2):79-83. PubMed ID: 25392249
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hallucinogen persisting perception disorder and the serotonergic system: a comprehensive review including new MDMA-related clinical cases.
    Litjens RP; Brunt TM; Alderliefste GJ; Westerink RH
    Eur Neuropsychopharmacol; 2014 Aug; 24(8):1309-23. PubMed ID: 24933532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The trip of a lifetime: hallucinogen persisting perceptual disorder.
    Anderson L; Lake H; Walterfang M
    Australas Psychiatry; 2018 Feb; 26(1):11-12. PubMed ID: 28836813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A retrospective analysis of the "Neverending Trip" after administration of a potent full agonist of 5-HT2A receptor - 25I-NBOMe.
    Schetz D; Schetz A; Kocić I
    Biomed Pharmacother; 2022 Feb; 146():112295. PubMed ID: 34980551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hallucinogenic Persisting Perception Disorder: A Case Series and Review of the Literature.
    Ford H; Fraser CL; Solly E; Clough M; Fielding J; White O; Van Der Walt A
    Front Neurol; 2022; 13():878609. PubMed ID: 35599738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hallucinogen persisting perception disorder after psilocybin consumption: a case study.
    Espiard ML; Lecardeur L; Abadie P; Halbecq I; Dollfus S
    Eur Psychiatry; 2005 Aug; 20(5-6):458-60. PubMed ID: 15963699
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hallucinogen persisting perception disorder: A literature review and three case reports.
    Skryabin VY; Vinnikova M; Nenastieva A; Alekseyuk V
    J Addict Dis; 2018; 37(3-4):268-278. PubMed ID: 31613183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Schizophrenia and hallucinogen persisting perception disorder: A clinical investigation.
    Lev-Ran S; Feingold D; Rudinski D; Katz S; Arturo LG
    Am J Addict; 2015 Apr; 24(3):197-199. PubMed ID: 25808913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flashback and Hallucinogen Persisting Perception Disorder: clinical aspects and pharmacological treatment approach.
    Lerner AG; Gelkopf M; Skladman I; Oyffe I; Finkel B; Sigal M; Weizman A
    Isr J Psychiatry Relat Sci; 2002; 39(2):92-9. PubMed ID: 12227234
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-reported psychopathological symptoms in recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation.
    Daumann J; Hensen G; Thimm B; Rezk M; Till B; Gouzoulis-Mayfrank E
    Psychopharmacology (Berl); 2004 May; 173(3-4):398-404. PubMed ID: 14722704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of "Ecstasy" blocked by serotonin reuptake inhibitors.
    Stein DJ; Rink J
    J Clin Psychiatry; 1999 Jul; 60(7):485. PubMed ID: 10453804
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.